Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34+ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia-Reference-Cited by-全球学者库

Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34+ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:10652-10653
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Shi Jun¹,Fang Riguo²,Gao Zhen¹,Shi Zhongyu²,Kuang Zhexiang¹,Zhang Yongjian²,Zhang Lele¹,Yang Huihui²,Zhang Yingchi¹,Zou Dehui¹,Fang Liwei¹,Sun Jiali¹,Li Qiang¹,Zou Yao¹,Pan Hong¹,Zhao Jingyu¹,Li Liyun¹,Yu Xiao¹,Xu Jing¹,Xu Chun¹,Liu Yanjie¹,Wang Weiwei¹,Shi Jia³,Liu Jie³,Wang Jia³,Shi Nian³,Yang Lei²,Wang Weiqiang²,Li Suyi³,Shi Moye²,Zhang Xiaoshuang²,Yuan Pengfei²,Wei Wensheng⁴,Wei Dong²,Cheng Tao¹

Affiliation:

1. 1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

2. 2EdiGene Inc., Beijing, China

3. 3EdiGene (Guangzhou) Inc., Guangzhou, China

4. 4Biomedical Pioneering Innovation Center, Beijing Advanced Innovation Center for Genomics, Peking-Tsinghua Center for Life Sciences, Peking University Genome Editing Research Center, State Key Laboratory of Protein and Plant Gene Research, Beijing, China

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR-Cas System: The Current and Emerging Translational Landscape;Cells;2023-04-07